Comprehensive Stock Comparison
Compare Virax Biolabs Group Limited (VRAX) vs Caris Life Sciences, Inc. (CAI) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  CAI | 97.0% revenue growth vs VRAX's -96.0% |
| Quality / Margins | CAI | -66.2% net margin vs VRAX's -78.6% |
| Stability / Safety | CAI | Beta 1.09 vs VRAX's 1.24, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | CAI | -29.1% vs VRAX's -84.6% |
| Efficiency (ROA) | CAI | -47.8% ROA vs VRAX's -199.1% |
Who Each Stock Is For
Income & stability
CAIDividend streak 4 yrs, beta 1.09
Growth exposure
CAIRev growth 97.0%, EPS growth -19.3%, 3Y rev CAGR 46.5%
Long-term compounding (10Y)
CAI-29.1% 10Y total return vs VRAX's -99.9%
Sleep-well-at-night portfolio
CAILower volatility, beta 1.09, Low D/E 0.0%, current ratio 7.85x
Defensive / Recession hedge
CAIBeta 1.09, current ratio 7.85x
Business Model
What each company does and how it makes money
Virax Biolabs Group is a biotechnology company focused on viral disease prevention, detection, and management through diagnostic test kits and medical technology products. It generates revenue primarily from selling diagnostic tests—including rapid antibody, antigen, and PCR tests under the ViraxClear brand—and medical/PPE products under the ViraxCare brand, distributed through clinics, pharmacies, hospitals, and an online platform. The company's competitive advantage lies in its integrated portfolio spanning diagnostics and protective equipment for viral diseases, serving both healthcare institutions and corporate clients across multiple international markets.
Caris Life Sciences is an AI-powered molecular diagnostics company that provides comprehensive cancer profiling services to guide treatment decisions. It generates revenue primarily from molecular testing services for oncology patients — including tissue-based and blood-based profiling — along with pharmaceutical research services for drug development partners. The company's competitive advantage lies in its extensive molecular database and proprietary AI algorithms that analyze complex biomarker data to deliver personalized cancer treatment insights.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
CAI 5
VRAX 0CAI4/4 metricsCAI2/3 metricsCAI8/8 metricsCAI6/6 metricsCAI2/2 metricsCAI leads in 5 of 6 categories — strongest in Financial Metrics and Valuation Metrics.
Financial Metrics (TTM)
CAI is the larger business by revenue, generating $812M annually — 4989.5x VRAX's $162,750. CAI is the more profitable business, keeping -66.2% of every revenue dollar as net income compared to VRAX's -78.6%.
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| RevenueTrailing 12 months | $162,750 | $812M |
| EBITDAEarnings before interest/tax | -$12M | $70M |
| Net IncomeAfter-tax profit | -$13M | -$538M |
| Free Cash FlowCash after capex | -$13M | $33M |
| Gross MarginGross profit ÷ Revenue | -1.5% | +46.2% |
| Operating MarginEBIT ÷ Revenue | -77.8% | +5.6% |
| Net MarginNet income ÷ Revenue | -78.6% | -66.2% |
| FCF MarginFCF ÷ Revenue | -77.3% | +4.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | -98.3% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +55.6% | — |
Valuation Metrics
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| Market CapShares × price | $2M | $33.2B |
| Enterprise ValueMkt cap + debt − cash | -$2M | $32.4B |
| Trailing P/EPrice ÷ TTM EPS | -0.11x | -6.17x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 62.06x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | 718.40x |
| Price / SalesMarket cap ÷ Revenue | 245.06x | 40.89x |
| Price / BookPrice ÷ Book value/share | 0.12x | 57.52x |
| Price / FCFMarket cap ÷ FCF | — | 496.41x |
Profitability & Efficiency
CAI delivers a -93.2% return on equity — every $100 of shareholder capital generates $-93 in annual profit, vs $-2 for VRAX. CAI carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to VRAX's 0.07x. On the Piotroski fundamental quality scale (0–9), CAI scores 5/9 vs VRAX's 1/9, reflecting solid financial health.
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| ROE (TTM)Return on equity | -2.3% | -93.2% |
| ROA (TTM)Return on assets | -199.1% | -47.8% |
| ROICReturn on invested capital | -2.7% | — |
| ROCEReturn on capital employed | -111.4% | +7.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 5 |
| Debt / EquityFinancial leverage | 0.07x | 0.00x |
| Net DebtTotal debt minus cash | -$4M | -$798M |
| Cash & Equiv.Liquid assets | $4M | $798M |
| Total DebtShort + long-term debt | $377,004 | $169,000 |
| Interest CoverageEBIT ÷ Interest expense | -149.04x | -2.23x |
Total Returns (with DRIP)
A $10,000 investment in CAI five years ago would be worth $7,093 today (with dividends reinvested), compared to $11 for VRAX. Over the past 12 months, CAI leads with a -29.1% total return vs VRAX's -84.6%. The 3-year compound annual growth rate (CAGR) favors CAI at -10.8% vs VRAX's -68.4% — a key indicator of consistent wealth creation.
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | -26.4% |
| 1-Year ReturnPast 12 months | -84.6% | -29.1% |
| 3-Year ReturnCumulative with dividends | -96.8% | -29.1% |
| 5-Year ReturnCumulative with dividends | -99.9% | -29.1% |
| 10-Year ReturnCumulative with dividends | -99.9% | -29.1% |
| CAGR (3Y)Annualised 3-year return | -68.4% | -10.8% |
Risk & Volatility
CAI is the less volatile stock with a 1.09 beta — it tends to amplify market swings less than VRAX's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CAI currently trades 46.7% from its 52-week high vs VRAX's 13.2% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 1.09x |
| 52-Week HighHighest price in past year | $1.58 | $42.50 |
| 52-Week LowLowest price in past year | $0.19 | $17.15 |
| % of 52W HighCurrent price vs 52-week peak | +13.2% | +46.7% |
| RSI (14)Momentum oscillator 0–100 | 37.3 | 38.4 |
| Avg Volume (50D)Average daily shares traded | 320K | 2.3M |
Analyst Outlook
| Metric | VRAXVirax Biolabs Gro… | CAICaris Life Scienc… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Buy |
| Price TargetConsensus 12-month target | — | $31.33 |
| # AnalystsCovering analysts | — | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 4 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | $99876.00 | $6331.00 | -93.7% |
| Caris Life Sciences… (CAI) | $294M | $812M | +175.9% |
Caris Life Sciences, Inc.'s revenue grew from $294M (2016) to $812M (2025) — a 11.9% CAGR.
Chart 2Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -8.0% | -957.4% | -11835.7% |
| Caris Life Sciences… (CAI) | 2.0% | -66.2% | -3351.8% |
Caris Life Sciences, Inc.'s net margin went from 2% (2016) to -66% (2025).
Chart 3EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Virax Biolabs Group… (VRAX) | -0.7 | -1.95 | -178.6% |
| Caris Life Sciences… (CAI) | 0.31 | -3.22 | -1138.7% |
Caris Life Sciences, Inc.'s EPS grew from $0.31 (2016) to $-3.22 (2025) — a NaN% CAGR.
Chart 4Free Cash Flow — 5 Years
Virax Biolabs Group Limited generated $-5M FCF in 2025 (-776% vs 2021). Caris Life Sciences, Inc. generated $67M FCF in 2025 (+120% vs 2022).
VRAX vs CAI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is VRAX or CAI a better buy right now?
Analysts rate Caris Life Sciences, Inc. (CAI) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VRAX or CAI?
Over the past 5 years, Caris Life Sciences, Inc. (CAI) delivered a total return of -29.1%, compared to -99.9% for Virax Biolabs Group Limited (VRAX). A $10,000 investment in CAI five years ago would be worth approximately $7K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CAI returned -29.1% versus VRAX's -99.9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VRAX or CAI?
By beta (market sensitivity over 5 years), Caris Life Sciences, Inc. (CAI) is the lower-risk stock at 1.09β versus Virax Biolabs Group Limited's 1.24β — meaning VRAX is approximately 14% more volatile than CAI relative to the S&P 500. On balance sheet safety, Caris Life Sciences, Inc. (CAI) carries a lower debt/equity ratio of 0% versus 7% for Virax Biolabs Group Limited — giving it more financial flexibility in a downturn.
04Which has better profit margins — VRAX or CAI?
Caris Life Sciences, Inc. (CAI) is the more profitable company, earning -66.2% net margin versus -957.4% for Virax Biolabs Group Limited — meaning it keeps -66.2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CAI leads at 5.6% versus -973.4% for VRAX. At the gross margin level — before operating expenses — CAI leads at 46.2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — VRAX or CAI?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is VRAX or CAI better for a retirement portfolio?
For long-horizon retirement investors, Caris Life Sciences, Inc. (CAI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.09)). Both have compounded well over 10 years (CAI: -29.1%, VRAX: -99.9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between VRAX and CAI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.